Verici Dx PLC Appointment of Non-executive Director (1046J)
19 Agosto 2021 - 1:00AM
UK Regulatory
TIDMVRCI
RNS Number : 1046J
Verici Dx PLC
19 August 2021
Verici Dx plc
("Verici Dx" or the "Company")
Appointment of Non-executive Director
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces the appointment to the
Board of Lorenzo Gallon, MD, as Non-executive Director with
immediate effect.
Professor of Medicine (Nephrology and Hypertension) and Surgery
(Organ Transplantation), Dr. Gallon is currently the Medical
Director of the Translational Medicine Program, the Director of
International Relations and the Director of the Renal Transplant
Fellowship at Northwestern University, He is an alumnus of the
University of Padua Medical School, Italy.
Dr. Gallon has extensive experience in nephrology and
hypertension as well as organ transplantation. He was a
collaborator and co-author with Dr. Barbara Murphy in the GoCar
study(1) , which was foundational in the development of Verici's
products. He has acted as an advisor / consultant for multiple
pharmaceutical and biotechnology companies, such as Alexion
Pharmaceuticals, Inc., Horizon Therapeutics, Inc., and Argenx
Pharma. He is also a member of the Editorial Board at the journal
Nephron since 2019. In 2012, Dr Gallon was part the Northwestern
Medicine transplant team that conducted the first successful
removal and implantation of a kidney from one patient to another
after the organ failed in the first recipient. The findings of the
case were published in the New England Journal of Medicine.
In March 2021, Verici Dx unveiled that it has partnered with Dr
Lorenzo Gallon, together with Dr Milagros Samaniego at Henry Ford
Health System and Dr Daniel G. Maluf at the University of Maryland,
Baltimore, in order to initiate the first US clinical trials for
its two lead products, Clarava(TM) and Tuteva(TM). The trial will
use next generation sequencing in the Verici laboratory to create
transcriptomic profiles to validate performance characteristics of
Clarava(TM) and Tuteva(TM). In the longer term, Verici is also
seeking to work on the validation of its fibrosis test.
Julian Baines, MBE, Non-executive Chairman of Verici Dx,
said:
"On behalf of the Board, I am delighted to welcome Lorenzo to
Verici Dx. He brings extensive experience counselling boards and
executives and will be an integral advisor helping us accelerate
innovation in kidney disease and transplantation, especially on
validation of our two lead products, Clarava(TM) and Tuteva(TM).
The wealth of clinical acumen Lorenzo brings will definitely add
value to the work we do every day on behalf of the millions of
patients who had or waiting for kidney transplant. We look forward
to embarking on our next phase of growth with our strengthened
Board."
Dr Lorenzo Gallon, Non-executive Director of Verici Dx,
said:
"I'm honoured to join the Verici Dx Board of Directors and share
my perspective as advisor with nearly 20 years of experience in the
life sciences industry, particularly in nephrology and organ
transplantation. I am glad to see the continuing development of
relationships between academics and biotechnology companies, and I
want to do all that I can to use my knowledge and experiences I've
obtained to help advance innovation in the treatment as well as
diagnostic testing of those who have kidney disease."
Regulatory Disclosures
Dr Lorenzo Giovanni Gallon, aged 56, currently has no
shareholding in the Company and there is no further information
required to be disclosed under Rule 17 or paragraph (g) of Schedule
2 of the AIM Rules for Companies.
(1) - https://pubmed.ncbi.nlm.nih.gov/27452608/
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser Tel: 020 7496 3000
& Broker)
Aubrey Powell / Kailey Aliyar / Tom
Salvesen
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07748 651 727
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand
how a patient will and is responding to organ transplant, with an
initial focus on kidney transplants. The body's own immune system
poses a threat to a successful transplant or graft. Patients'
immune systems differ in how they respond to the presence of the
transplanted organ, characterising this response is called immune
phenotyping. Our products and solutions are underpinned by
extensive scientific research into the recipient's immune phenotype
and how that impacts on acute rejection, chronic injury and
ultimately failure of the transplant. These immuno-profile
signatures also inform clinicians as to the optimal strategy for
immunosuppressive and other therapies for the most successful
treatment to ensure graft acceptance with the least amount of side
effects.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADKFBQDBKBPFD
(END) Dow Jones Newswires
August 19, 2021 02:00 ET (06:00 GMT)
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
